Essa Pharma Inc.
USPTO PatentsView assignee record - 7 granted patents across 5 technology areas, recorded in grant years 2021–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Essa ranks #35,230 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 5 technology areas.
- #35,230
- of 49,997 US assignees by volume
- Top 14%
- by Innovation Score (50.1/100)
- 25.6
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R35230 · Foreign Corporation #35,230 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 7 grants
- MID-PACK #35,230/49,997
- PHOTO-FINISH Equalia
- CPC-NARROW A61P · 5 areas
- INNOV-PAR 50.1/100
- CLAIMS-DENSE 25.6 claims/avg
- TYPE-FRNCORP Foreign Corp
- SPAN-YRS 2021–2024 · 4y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Equalia LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Essa’s 50.1 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Essa
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Blackshark ai · near
Blackshark ai · near
50 score
- Essa Pharma · this assignee
Essa Pharma · this assignee
50 score
- Iogen · near
Iogen · near
50 score
- Stego-holding · near
Stego-holding · near
50 score
- Torrey Pines Logic · near
Torrey Pines Logic · near
50 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Essa's Innovation Score is 50.1/100 (top 14% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Essa?
Each dot is one of Essa’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Essa’s own 25.6 claims/patent is ABOVE the 13.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Essa's grants concentrate
Essa Pharma Inc. is a focused PatentsView assignee: 5 CPC subclasses with 85.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (4 grants) versus a trough of 1 in 2021. By volume, Essa sits between Equalia LLC and Etherwhere Corporation.
Essa's three-year grant acceleration
Essa Pharma Inc. shows 6 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Essa's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Equalia
Equalia LLC
7 patents
- Eskom Holdings SOC
Eskom Holdings SOC Limited
7 patents
- ESM Energie—UND S…
ESM ENERGIE—UND Schwingungstechnik Mitsch GMBH
7 patents
- Esperance Pharmac…
Esperance Pharmaceuticals, Inc.
7 patents
- Essencore
Essencore Limited
7 patents
- Estar
Estar Technologies Ltd.
7 patents
- Etablissements Pi…
Etablissements Pierre Grehal ET CIE S.A.
7 patents
- Etherwhere
Etherwhere Corporation
7 patents
- Essa Pharma ◀
Essa Pharma Inc.
7 patents
What this shows Essa holds 7 patents at rank #35,162, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Essa
By rank, the assignees closest to #35,162 in granted patent volume.
- Equalia LLC #35,158 · 7 patents
- Eskom Holdings SOC Limited #35,159 · 7 patents
- ESM ENERGIE—UND Schwingungstechnik Mitsch GMBH #35,160 · 7 patents
- Esperance Pharmaceuticals, Inc. #35,161 · 7 patents
- Essencore Limited #35,163 · 7 patents
- Estar Technologies Ltd. #35,164 · 7 patents
- Etablissements Pierre Grehal ET CIE S.A. #35,165 · 7 patents
- Etherwhere Corporation #35,166 · 7 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Essa's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Essa, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Essa ranks #2,984 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (50 here).
Essa's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
50 Top 14% higher than 86% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 1 | 14.3% |
| 2022 | 4 | 57.1% |
| 2023 | 1 | 14.3% |
| 2024 | 1 | 14.3% |
Which technologies does Essa Pharma Inc. patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Essa Pharma Inc.'s patent record in context - here's where to go next.
- Essa Pharma Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85.7% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #35,230 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Essa Pharma Inc. against Equalia LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 50.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.